HAVCR2 and neoplasm: At present, there are many other immune checkpoints been discovered and served as drug targets, such as CTLA-4, TIM-3, LAG-3, TIGIT, VISTA, etc. As some drugs enter clinical trials and daily practice, PD-1/PD-L1 inhibitors combined with other checkpoint blockers have shown significant immune response and tumor shrinkage.